MK2 Inhibitors as a Potential Crohn's Disease Treatment Approach for Regulating MMP Expression, Cleavage of Checkpoint Molecules and T Cell Activity.

Lebish, Eric J; Morgan, Natalie J; Valentine, John F; Beswick, Ellen J

Lebish, Eric J; Morgan, Natalie J; Valentine, John F; Beswick, Ellen J.

Afiliación

Lebish EJ; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84112, USA.
Morgan NJ; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84112, USA.
Valentine JF; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84112, USA.
Beswick EJ; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84112, USA.

Pharmaceuticals (Basel) ; 15(12)2022 Dec 03.

Article en En | MEDLINE | ID: mdl-36558958

Palabras clave

Crohn's Disease; Lag3; MAPKAPK2; MK2; PD-L1; checkpoint molecules; inflammatory bowel disease; matrix metalloproteinases (MMPs)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos